Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Crofelemer

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 7,823Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Jaguar Inks $38M U.S. Crofelemer License Deal With Future Pak
    Jaguar Inks $38M U.S. Crofelemer License Deal With Future Pak

    12 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-12/jaguar-health-enters-into-us-license-agreement-with-future-pak-for-crofelemer-providing-up-to-38

    PHARMIWEB
    12 Jan 2026
    Share Share
    Jaguar Health's Crofelemer Study Shows Promising Results
    Jaguar Health's Crofelemer Study Shows Promising Results

    06 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-06/article-about-groundbreaking-results-from-study-of-jaguar-healths-crofelemer-for-treatment-of-intes

    PHARMIWEB
    06 Jan 2026
    Share Share
    Jaguar Health Announces Abstract Submission for Preliminary Data
    Jaguar Health Announces Abstract Submission for Preliminary Data

    15 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-15/jaguar-health-announces-abstract-submission-for-preliminary-data-from-us-investigator-initiated-tria

    PHARMIWEB
    15 Dec 2025
    Share Share
    FDA Renews Canalevia-CA1 Approval for Chemo Diarrhea
    FDA Renews Canalevia-CA1 Approval for Chemo Diarrhea

    10 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-10/fda-approves-renewal-of-canalevia-ca1-jaguar-healths-drug-for-chemotherapy-induced-diarrhea-cid

    PHARMIWEB
    10 Dec 2025
    Share Share
    Jaguar Health Approves All Proposals at December 2025 Meeting
    Jaguar Health Approves All Proposals at December 2025 Meeting

    08 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-08/jaguar-health-reports-approval-of-all-proposals-at-december-2025-special-meeting-of-stockholders

    PHARMIWEB
    08 Dec 2025
    Share Share
    Jaguar Health Files EMA Application for Canalevia in Dogs
    Jaguar Health Files EMA Application for Canalevia in Dogs

    02 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-02/jaguar-health-makes-submission-to-ema-regarding-eu-approval-pathway-for-canalevia-for-general-diarrh

    PHARMIWEB
    02 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.